Your Patients Need Cladribine — Here's How to Help Them Get It

You've made the clinical decision to start a patient on Cladribine (Mavenclad) for relapsing MS. The evidence supports it, the patient is a good candidate, and you've discussed the risks and benefits. Now comes the hard part: actually getting the medication into their hands.

For too many patients, the gap between prescription and first dose stretches from days into weeks — or longer. As a provider, you're in a unique position to accelerate this process. This guide covers what's causing delays and what your practice can do about it.

Current Availability of Cladribine

As of early 2026, Mavenclad is not in a formal shortage. EMD Serono continues to manufacture and distribute the brand-name product through specialty pharmacies. The FDA also approved generic Cladribine tablets (Apotex Inc.) in November 2025, adding a second source of supply.

The access challenges are systemic, not supply-driven:

• Exclusive specialty pharmacy distribution
• Prior authorization and step therapy requirements
• Coordination delays between prescribers, insurers, and pharmacies
• Patient confusion about the process

Why Patients Can't Find Cladribine

Understanding the patient experience helps clarify where your practice can intervene:

They Don't Know It's a Specialty Medication

Many patients expect to fill Mavenclad at their regular pharmacy. When told it requires a specialty pharmacy, they may not know what that means or how to proceed. Setting expectations at the prescribing visit is crucial.

Prior Authorization Delays

Most payers require prior authorization for Mavenclad. Processing time ranges from 3-14 business days under standard timelines. Incomplete documentation — missing MRI results, inadequate documentation of prior DMT failures, or unsigned forms — is the most common cause of delays and denials.

The Specialty Pharmacy Intake Process

Once a prescription reaches the specialty pharmacy, there's often a secondary intake process: verifying insurance, collecting patient demographic and clinical information, and scheduling delivery. This can add another 3-7 business days.

Cost Shock

Patients who see the list price of ~$99,500/year may panic and delay filling the prescription. Proactive cost conversations at the point of prescribing can prevent this.

What Providers Can Do: 5 Steps

Step 1: Submit Prior Authorization at the Time of Prescribing

Don't wait for the patient to contact the specialty pharmacy first. Initiate the PA the same day you write the prescription. Ensure your documentation includes:

• Confirmed diagnosis of relapsing MS (ICD-10: G35)
• History of prior DMT use and reasons for discontinuation/failure
• Recent MRI results showing disease activity
• Lab results confirming eligibility (lymphocyte counts, HIV/hepatitis/TB screening)
• Clinical rationale for Cladribine over other available DMTs

Step 2: Identify the Patient's Preferred Specialty Pharmacy

Contact the patient's insurance to confirm which specialty pharmacy is in-network. If the preferred pharmacy doesn't have Cladribine in stock, ask if the plan allows an alternative specialty pharmacy. Use Medfinder for Providers to check real-time availability across specialty pharmacies.

Step 3: Enroll the Patient in MS LifeLines

EMD Serono's MS LifeLines (1-800-283-8088) is a comprehensive support program that can:

• Conduct a benefits investigation on the patient's behalf
• Handle copay program enrollment (commercially insured patients may pay $0-$25)
• Provide patient assistance for uninsured/underinsured patients (free medication)
• Assign an MS-certified nurse for patient education and support
• Coordinate with specialty pharmacies on the provider's behalf

Enrolling the patient in MS LifeLines at the prescribing visit — rather than waiting for them to encounter a cost barrier — can prevent delays down the line.

Step 4: Set Patient Expectations

At the prescribing visit, explain:

• Cladribine is a specialty medication — it won't be at their regular pharmacy
• The process typically takes 2-4 weeks from prescription to delivery
• They'll likely receive a phone call from the specialty pharmacy for intake
• Financial assistance is available (copay program, patient assistance)
• They should contact your office if they don't hear from the pharmacy within 7-10 days

Step 5: Create a Follow-Up Workflow

Build a system to track patients in the "prescribed but not yet treated" stage:

• Flag the patient's chart for follow-up 7 days after prescribing
• Assign a staff member to check PA status and specialty pharmacy processing
• If PA is denied, file an appeal promptly with supporting documentation
• Confirm delivery date and schedule the patient's first treatment cycle

Alternatives to Consider

If Cladribine access is delayed beyond what's clinically acceptable, discuss alternatives with the patient:

• Ocrelizumab (Ocrevus): High-efficacy IV infusion every 6 months; may be easier to obtain through infusion center channels
• Fingolimod (Gilenya): Oral daily; generics available, improving access and cost
• Dimethyl Fumarate (Tecfidera): Oral twice daily; generics widely available
• Siponimod (Mayzent): Oral daily; approved for relapsing and secondary progressive MS

See our patient-facing alternatives guide for more detail.

Workflow Tips for Your Practice

• Template your PA letters: Create a Cladribine-specific prior authorization template that includes all commonly required clinical criteria. Pre-populate patient demographics and diagnosis codes.
• Batch your PA submissions: If you have multiple patients on or starting Cladribine, designate specific days for PA processing to improve efficiency.
• Track treatment cycles: Mavenclad has 4 treatment cycles over 2 years. Build reminders into your EHR for each cycle so PA renewals and pharmacy coordination start early.
• Use e-prescribing: Send prescriptions electronically to specialty pharmacies when possible. This avoids fax delays and reduces transcription errors.
• Document everything: Insurance appeals for Cladribine denials succeed more often when supported by detailed clinical documentation. Note prior DMT history, reasons for switching, and disease activity evidence in the chart.

Final Thoughts

The clinical case for Cladribine is often straightforward. It's the administrative process that creates friction. By building specialty pharmacy coordination, PA submission, and patient support enrollment into your prescribing workflow — rather than treating them as afterthoughts — you can meaningfully reduce the time between prescription and treatment.

For real-time availability information, use Medfinder for Providers. For the broader clinical and access landscape, see our provider briefing on Cladribine in 2026. And for a cost-focused resource to share with patients, see our guide on helping patients save money on Cladribine.